Aclaris Therapeutics (ACRS) Accumulated Expenses (2014 - 2026)

Aclaris Therapeutics' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 31.22% year-over-year to $5.9 million in Q1 2026; TTM through Mar 2026 was $5.9 million, a 31.22% decrease from a year earlier, with the FY2025 full-year figure at $8.8 million, up 76.56% from the prior year.
• Accumulated Expenses declined to $5.9 million in Q1 2026 per ACRS's latest filing, from $8.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $9.2 million in Q3 2022 and bottomed at $2.6 million in Q1 2024.
• The 5-year median for Accumulated Expenses is $5.0 million (2023), against an average of $4.9 million.
• Across the five-year window, Accumulated Expenses slumped 58.38% in 2022 and jumped 231.22% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $5.3 million in 2022, then dropped by 26.16% to $3.9 million in 2023, then increased by 27.34% to $5.0 million in 2024, then surged by 76.56% to $8.8 million in 2025, then sank by 32.93% to $5.9 million in 2026.
• Per Business Quant, the three latest ACRS Accumulated Expenses figures stand at $5.9 million (Q1 2026), $8.8 million (Q4 2025), and $3.8 million (Q3 2025).